| Q47107002 | "HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer. |
| Q47931999 | A Novel Absorbable Radiopaque Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum in Radiation Therapy for Pancreatic Cancer |
| Q64261381 | A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer? |
| Q64267929 | A Review of Pancreatic Cancer: Epidemiology, Genetics, Screening, and Management |
| Q28077111 | A current perspective on stereotactic body radiation therapy for pancreatic cancer |
| Q64255367 | A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer |
| Q64903865 | Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. |
| Q93379624 | Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005 |
| Q97532176 | Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence |
| Q47874606 | An evaluation of motion mitigation techniques for pancreatic SBRT. |
| Q90618621 | An update on treatment options for pancreatic adenocarcinoma |
| Q58566409 | Application of stereotactic body radiotherapy in advanced pancreatic cancers in Australia |
| Q36391055 | Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: An exploratory study |
| Q47614694 | Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study. |
| Q92533693 | Berbamine Enhances the Efficacy of Gefitinib by Suppressing STAT3 Signaling in Pancreatic Cancer Cells |
| Q39156722 | Biological determinants of radioresistance and their remediation in pancreatic cancer |
| Q38801235 | Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy |
| Q50043555 | Characterizing the potency and impact of carbon ion therapy in a primary mouse model of soft tissue sarcoma. |
| Q38746213 | Charged-particle therapy in cancer: clinical uses and future perspectives |
| Q60922867 | Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer |
| Q64935949 | Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. |
| Q39234276 | Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection |
| Q57824846 | Chemotherapy in Pancreatic Cancer: A Systematic Review |
| Q50073661 | Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer |
| Q92635669 | Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer |
| Q41386937 | Clinical Practice Guidelines for Cryosurgery of Pancreatic Cancer: A Consensus Statement From the China Cooperative Group of Cryosurgery on Pancreatic Cancer, International Society of Cryosurgery, and Asian Society of Cryosurgery. |
| Q55512487 | Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. |
| Q54974682 | Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac. |
| Q60922811 | Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle |
| Q50012127 | Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer |
| Q89622377 | Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer |
| Q64113841 | Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer |
| Q64086645 | Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies |
| Q89622514 | Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer |
| Q92931846 | Contemporary management of borderline resectable pancreatic ductal adenocarcinoma |
| Q89994568 | Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis |
| Q33676692 | Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy. |
| Q90194029 | Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions |
| Q58784454 | Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy |
| Q38673621 | Current and future therapies for advanced pancreatic cancer |
| Q48221094 | Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. |
| Q41651225 | Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer |
| Q33713919 | Design, synthesis, and biological evaluation of novel EF24 and EF31 analogs as potential IκB kinase β inhibitors for the treatment of pancreatic cancer |
| Q64054091 | Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study |
| Q95642741 | Disease Site-Specific Guidelines for Curative Radiation Treatment During 'Limited Surgery' and 'Hospital Avoidance': A Radiation Oncology Perspective From the Epicenter of COVID-19 Pandemic |
| Q92347638 | Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer? |
| Q92523349 | Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer |
| Q64997389 | Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study. |
| Q58119172 | Dose escalation for locally advanced pancreatic cancer: How high can we go? |
| Q58608661 | Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer |
| Q43379696 | Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. |
| Q89729352 | Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach |
| Q42375843 | Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients |
| Q64326445 | Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer |
| Q57494901 | Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer |
| Q58759296 | Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials |
| Q92347561 | Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial) |
| Q33441606 | Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data |
| Q39158411 | Emerging protein kinase inhibitors for treating pancreatic cancer |
| Q50221174 | Essential role of radiation therapy for the treatment of pancreatic cancer : Novel study concepts and established treatment recommendations |
| Q94544900 | Evaluating dosimetric constraints for carbon ion radiotherapy in the treatment of locally advanced pancreatic cancer |
| Q59335153 | Evaluation of Dynamic Tumor-tracking Intensity-modulated Radiotherapy for Locally Advanced Pancreatic Cancer |
| Q50106247 | Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis |
| Q92837898 | Evaluation of a simplified optimizer for MR-guided adaptive RT in case of pancreatic cancer |
| Q92442030 | Evaluation of the effects of motion mitigation strategies on respiration-induced motion in each pancreatic region using cine-magnetic resonance imaging |
| Q38624806 | Evolving treatment landscape for early and advanced pancreatic cancer |
| Q90004902 | Extensive Unpredictable Pancreas Cancer Inter-fraction Motion: A Case Report |
| Q59137774 | FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study |
| Q90244152 | FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study |
| Q37631655 | From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers |
| Q38935821 | Having Your Cake and Eating It Too: Combining SBRT and Multi-agent Chemotherapy in Locally Advanced Pancreatic Cancer |
| Q96305349 | How Much Was the Elective Lymph Node Region Covered in Involved-Field Radiation Therapy for Locally Advanced Pancreatic Cancer? Evaluation of Overlap Between Gross Target Volume and Celiac Artery-Superior Mesenteric Artery Lymph Node Regions |
| Q52617943 | Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. |
| Q58130520 | Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy |
| Q38406521 | Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study |
| Q58789567 | Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancers |
| Q64231807 | Intrasplenic Pancreatic Pseudocyst after Chemoradiation of a Pancreatic Adenocarcinoma Mimicking Progressive Disease: A Case Report and Review of the Literature |
| Q92600987 | Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model |
| Q50100093 | Irreversible electroporation of pancreatic adenocarcinoma: a primer for the radiologist |
| Q64083421 | Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis |
| Q60922836 | Large database utilization in health outcomes research in pancreatic cancer: an update |
| Q48270496 | Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. |
| Q92279402 | Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma |
| Q41055466 | Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer |
| Q50054472 | Management and survival analysis of elderly patients with a cancer in the digestive system who refused to receive anticancer treatments |
| Q39371353 | Management of unresectable, locally advanced pancreatic adenocarcinoma. |
| Q93379631 | Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer |
| Q38722475 | Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer |
| Q92737734 | Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study |
| Q104500105 | Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial |
| Q90413913 | Neoadjuvant Treatment in Pancreatic Cancer |
| Q58611183 | Neoadjuvant and adjuvant chemotherapy in pancreatic cancer |
| Q55406377 | Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment. |
| Q97542021 | On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations |
| Q91617783 | Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls |
| Q38792423 | Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation |
| Q90273327 | Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study |
| Q92483772 | PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers |
| Q39390859 | Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies |
| Q96770049 | Pancreatic cancer |
| Q59329755 | Pancreatic cancer: challenges and opportunities |
| Q92423104 | Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan |
| Q88495157 | Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database |
| Q91735873 | Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer |
| Q37738012 | Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic cancer |
| Q38673039 | Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer |
| Q92637158 | Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer |
| Q37151116 | Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). |
| Q64227463 | Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy |
| Q88710512 | Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer |
| Q90346450 | Proton beam radiotherapy for pancreas cancer |
| Q41598639 | Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma |
| Q38939835 | Quantitative Proteomic Analysis of Serum Exosomes from Patients with Locally Advanced Pancreatic Cancer Undergoing Chemoradiotherapy. |
| Q55038620 | Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn't! |
| Q93050532 | Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy |
| Q92782751 | Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line |
| Q48235100 | Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients |
| Q90665403 | Radiotherapy as an Adjunct to Surgery for Pancreatic Cancer: Where Are We After More Than 30 Years of Research and Trials? |
| Q60956564 | Recent advances in radiation therapy of pancreatic cancer |
| Q90149903 | Recent advances in the treatment of pancreatic cancer |
| Q93334976 | Recommendations on the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19 |
| Q41039836 | Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma |
| Q47998977 | Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. |
| Q42368801 | Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure |
| Q60922820 | Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma |
| Q88991106 | Role of Adjuvant Chemoradiotherapy for Duodenal Cancer: An Updated Analysis of Long-Term Follow-Up from Single Institution |
| Q47926291 | Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. |
| Q55162030 | Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. |
| Q90612384 | Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment |
| Q55313697 | Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer: A Promising Approach. |
| Q55284451 | Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer. |
| Q57811272 | Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity |
| Q64052570 | Stereotactic body radiation therapy for locally advanced pancreatic cancer |
| Q40141235 | Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. |
| Q47146583 | Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer-patterns of care and overall survival |
| Q38806110 | Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy. |
| Q38678790 | Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. |
| Q58731700 | Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study |
| Q39312912 | Surgical strategies and novel therapies for locally advanced pancreatic cancer |
| Q88213642 | Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection |
| Q42366470 | Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft. |
| Q54974100 | Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. |
| Q92076388 | Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy |
| Q64107988 | The Challenges of Informed Consent in High-Stakes, Randomized Oncology Trials: A Systematic Review |
| Q64950912 | The Management of Older Adults with Pancreatic Adenocarcinoma. |
| Q48599351 | The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. |
| Q39364761 | The Role of Consolidation Chemo-Radiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis |
| Q49180532 | The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition |
| Q40531561 | The results of the LAP07 trial should not be misunderstood as the end of chemoradiotherapy in pancreatic cancer |
| Q92159193 | The role of biological dose-escalation for pancreatic cancer |
| Q48354898 | The role of imaging in the clinical practice of radiation oncology for pancreatic cancer |
| Q65002154 | The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer. |
| Q60609561 | Therapeutic developments in pancreatic cancer: current and future perspectives |
| Q92462964 | Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy |
| Q88816174 | Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial |
| Q90218758 | Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers |
| Q89966987 | Upregulated Expression of TUBA1C Predicts Poor Prognosis and Promotes Oncogenesis in Pancreatic Ductal Adenocarcinoma via Regulating the Cell Cycle |
| Q57494900 | Use of radiotherapy in patients with palliative double bypass for locally advanced pancreatic adenocarcinoma |
| Q64885330 | Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. |
| Q55119439 | Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. |
| Q89771098 | Volume de-escalation in radiation therapy: state of the art and new perspectives |
| Q38689025 | What treatment in 2017 for inoperable pancreatic cancers? |
| Q57109364 | [Palliative therapy concepts for pancreatic carcinoma] |
| Q57172464 | [Pancreatic ductal adenocarcinoma] |
| Q89482203 | [Role of stereotactic body radiation therapy for unresected pancreatic cancer] |
| Q50046512 | microRNA-193a stimulates pancreatic cancer cell repopulation and metastasis through modulating TGF-β2/TGF-βRIII signalings |
| Q58760423 | p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation |